Natus Medical Incorporated (NTUS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Natus Medical Incorporated (NTUS) trades at $32.96 with AI Score 50/100 (Grade B). Natus Medical Incorporated provides medical device solutions for the diagnosis and treatment of central nervous and sensory system disorders. Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for NTUS: NTUS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NTUS against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NTUS: 4/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.
Natus Medical Incorporated (NTUS) Healthcare & Pipeline Overview
Natus Medical Incorporated delivers medical device solutions for diagnosing and treating central nervous and sensory system disorders globally. With a focus on newborn care, hearing impairment, and neurological conditions, the company offers screening, detection, and monitoring technologies, positioning itself as a key player in the medical devices sector.
What Is the Investment Thesis for NTUS?
Natus Medical Incorporated presents a mixed investment thesis. The company's established position in the medical device market, particularly in newborn care and neurodiagnostics, provides a stable revenue base. Its gross margin of 57.8% indicates strong pricing power. However, a high P/E ratio of 84.98 suggests the stock may be overvalued relative to its earnings. The company's beta of 0.23 indicates low volatility compared to the market. Growth catalysts include expanding its product offerings and penetrating emerging markets. Potential risks include increasing competition and regulatory changes in the healthcare industry. Investors should carefully weigh the valuation against growth prospects and potential headwinds.
Based on FMP financials and quantitative analysis
NTUS Key Highlights
- Gross Margin of 57.8% demonstrates strong pricing power in the medical device market.
- P/E Ratio of 84.98 indicates a potentially high valuation relative to earnings.
- Beta of 0.23 suggests lower volatility compared to the broader market.
- Focus on newborn care and neurodiagnostics provides a stable revenue base.
- Global presence allows for diversification and access to multiple markets.
Who Are NTUS's Competitors?
NTUS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NPCE NeuroPace, Inc. | $15.89 | +0.32% | $541.75M | 65 |
| ATRWF Altius Renewable Royalties Corp. | $8.50 | +0.00% | $262.46M | 64 |
| LFTSF LifeTech Scientific Corporation | $0.23 | +0.00% | $1.03B | 63 |
| MYO Myomo, Inc. | $1.20 | -12.41% | $46.37M | 62 |
| DRWKF Drägerwerk AG & Co. KGaA | $100.47 | -9.96% | $1.88B | 50 |
| VASC Vascular Solutions LLC | $56.00 | +0.00% | 51 | |
| STJ St. Jude Medical, Inc. | $80.82 | +0.01% | 50 | |
| IOBCF Ion Beam Applications S.A. | $19.36 | -3.68% | $567.79M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NTUS's Key Strengths?
- Strong market position in newborn care and neurodiagnostics.
- Comprehensive product portfolio.
- Global presence.
- Established relationships with key customers.
What Are NTUS's Weaknesses?
- High P/E ratio may indicate overvaluation.
- Dependence on specific product lines.
- Exposure to regulatory changes in the healthcare industry.
- Competition from larger medical device companies.
What Could Drive NTUS Stock Higher?
- Potential for new product launches in the neurodiagnostics space.
- Expansion into emerging markets with growing healthcare infrastructure.
- Strategic partnerships with healthcare providers to enhance service offerings.
What Are the Key Risks for NTUS?
- Increased competition from established medical device companies.
- Regulatory changes impacting the approval and reimbursement of medical devices.
- Economic downturn affecting healthcare spending.
- Technological obsolescence requiring continuous innovation.
What Are the Growth Opportunities for NTUS?
- Expansion in Emerging Markets: Natus can expand its presence in emerging markets, such as Asia-Pacific and Latin America, where healthcare infrastructure is developing and demand for medical devices is increasing. These markets offer significant growth potential due to their large populations and rising healthcare expenditure. Successfully penetrating these markets could significantly boost Natus's revenue and market share. Timeline: Ongoing.
- New Product Development: Investing in research and development to create innovative medical devices and solutions can drive future growth. Focusing on areas such as advanced neurodiagnostics, telemedicine, and remote patient monitoring can capitalize on emerging trends in healthcare. Introducing new products can attract new customers and increase revenue from existing customers. Timeline: Ongoing.
- Strategic Acquisitions: Acquiring complementary businesses and technologies can expand Natus's product portfolio and market reach. Targeting companies with innovative technologies or strong market positions in adjacent areas can create synergies and accelerate growth. Strategic acquisitions can also provide access to new customer segments and geographic markets. Timeline: Ongoing.
- Telemedicine Integration: Integrating its medical devices with telemedicine platforms can expand Natus's reach and improve patient access to care. Telemedicine is becoming increasingly popular, especially in rural areas and for patients with mobility issues. By offering telemedicine-enabled solutions, Natus can tap into this growing market and differentiate itself from competitors. Timeline: Ongoing.
- Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and other healthcare providers can create new opportunities for Natus. Partnering with these organizations to offer comprehensive solutions and services can improve patient outcomes and increase revenue. These partnerships can also provide valuable insights into customer needs and market trends. Timeline: Ongoing.
What Opportunities Does NTUS Have?
- Expansion in emerging markets.
- New product development.
- Strategic acquisitions.
- Telemedicine integration.
What Threats Does NTUS Face?
- Increasing competition.
- Technological obsolescence.
- Economic downturn.
- Changes in healthcare reimbursement policies.
What Are NTUS's Competitive Advantages?
- Specialized product portfolio focused on niche markets.
- Strong brand reputation in newborn care and neurodiagnostics.
- Established relationships with key customers in the healthcare industry.
- Proprietary technologies and intellectual property.
What Does NTUS Do?
Natus Medical Incorporated, originally founded as ALGOTEK Instruments, Inc. in 1987 and renamed in 1988, is a global provider of medical device solutions focused on the diagnosis and treatment of patients with central nervous and sensory system disorders. Headquartered in Middleton, Wisconsin, the company offers a comprehensive portfolio of products and technologies used for screening, detection, treatment, monitoring, and tracking of common medical ailments. These include solutions for newborn care, addressing conditions such as jaundice and brain injury; hearing impairment, providing hearing assessment and instrument fitting solutions; neurological and neurosurgical treatments, offering electroencephalography and intra-operative monitoring solutions; epilepsy, sleep disorders, and neuromuscular diseases. Natus also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, along with software systems for managing and tracking disorders and diseases for public health laboratories. The company's products are utilized in various settings, including university medical centers, public and private hospitals, physician offices, clinics, and research laboratories. Natus aims to improve patient outcomes through innovative medical technologies and comprehensive solutions.
What Products and Services Does NTUS Offer?
- Develops and markets medical devices for diagnosing and treating central nervous and sensory system disorders.
- Offers solutions for newborn care, including jaundice management and brain injury products.
- Provides hearing assessment and screening solutions for hearing impairment.
- Offers neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology.
- Provides software systems for managing and tracking disorders and diseases for public health laboratories.
- Offers electroencephalography, long term monitoring, and intra-operative monitoring solutions.
- Provides balance assessment systems to evaluate patients with balance disorders.
- Offers NICVIEW, a live streaming video for families with babies in the NICU.
How Does NTUS Make Money?
- Develops and manufactures medical devices and software solutions.
- Sells products directly to hospitals, clinics, and other healthcare providers.
- Generates revenue through product sales and service contracts.
- Invests in research and development to create new and innovative products.
What Industry Does NTUS Operate In?
Natus Medical Incorporated operates in the medical device industry, which is characterized by continuous innovation and increasing demand for advanced diagnostic and treatment solutions. The industry is driven by factors such as an aging population, rising prevalence of chronic diseases, and technological advancements. The competitive landscape includes major players in medical devices and specialized companies focusing on neurodiagnostics and newborn care. Natus's focus on specific niches within this market allows it to maintain a competitive edge through specialized products and services. The global medical devices market is projected to reach significant growth in the coming years, driven by increasing healthcare expenditure and technological advancements.
Who Are NTUS's Key Customers?
- University medical centers
- Public and private hospitals
- Physician offices and clinics
- Research laboratories
NTUS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Natus Medical's future prospects, indicating that executives believe in the company's growth potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative product pipeline and its impact on healthcare.
- Recent partnerships and collaborations have garnered attention, enhancing Natus Medical's market presence and credibility among investors.
- The overall healthcare sector remains robust, with increasing demand for medical devices, positioning Natus Medical favorably in a growing market.
Bear Case
- Concerns over regulatory challenges in the medical device industry have surfaced, creating uncertainty around Natus Medical's operational environment.
- Recent earnings calls revealed potential supply chain issues that could impact product availability and revenue generation.
- Community sentiment has shown skepticism regarding the company’s ability to maintain competitive advantages against larger players in the market.
- Market perception has been cautious, with some analysts questioning the sustainability of Natus Medical's growth amidst broader economic challenges.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
NTUS Latest News
-
Earnings Scheduled For November 4, 2021
· Nov 4, 2021
-
Earnings Scheduled For May 6, 2021
· May 6, 2021
-
Stocks That Hit 52-Week Highs On Thursday
· Apr 15, 2021
-
Earnings Scheduled For July 30, 2020
· Jul 30, 2020
NTUS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NTUS.
Price Targets
Wall Street price target analysis for NTUS.
NTUS MoonshotScore
What does this score mean?
The MoonshotScore rates NTUS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jonathan Kennedy
CEO
Information on Jonathan Kennedy's background is not available in the provided context. Without additional data, it's impossible to provide details on his career history, education, or previous roles.
Track Record: Information on Jonathan Kennedy's track record is not available in the provided context. Without additional data, it's impossible to provide details on key achievements, strategic decisions, or company milestones under his leadership.
NTUS Healthcare Stock FAQ
What does Natus Medical Incorporated do?
Natus Medical Incorporated specializes in providing medical device solutions for the diagnosis and treatment of central nervous and sensory system disorders. The company offers a range of products and technologies used in newborn care, hearing impairment, neurological treatments, and sleep disorder management. These solutions include neurodiagnostic systems, hearing assessment tools, and neonatal care products, serving university medical centers, hospitals, and clinics globally. Natus focuses on improving patient outcomes through innovative medical technologies.
What are the main risks for NTUS?
The main risks for Natus Medical Incorporated include increasing competition in the medical device industry, which could pressure pricing and market share. Regulatory changes in healthcare could impact the approval and reimbursement of Natus's products, affecting revenue. An economic downturn could reduce healthcare spending, impacting demand for the company's solutions. Additionally, technological obsolescence poses a risk, requiring continuous investment in research and development to maintain a competitive edge. These factors could impact Natus's financial performance and growth prospects.
What are the key factors to evaluate for NTUS?
Natus Medical Incorporated (NTUS) holds an AI score of 50/100 (moderate). P/E: 85.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does NTUS data refresh on this page?
NTUS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NTUS's recent stock price performance?
Natus Medical Incorporated (NTUS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in newborn care and neurodiagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NTUS overvalued or undervalued right now?
Natus Medical Incorporated (NTUS) trades at 85.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NTUS?
Before investing in Natus Medical Incorporated (NTUS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding NTUS to a portfolio?
Key strength of Natus Medical Incorporated (NTUS): Strong market position in newborn care and neurodiagnostics. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may not be exhaustive.
- Financial metrics are as of the latest available reporting period.